These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 34290505)
1. Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials. Diekamp B; Borentain S; Fu DJ; Murray R; Heerlein K; Zhang Q; Schüle C; Mathews M Neuropsychiatr Dis Treat; 2021; 17():2347-2357. PubMed ID: 34290505 [TBL] [Abstract][Full Text] [Related]
2. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217 [TBL] [Abstract][Full Text] [Related]
3. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700 [TBL] [Abstract][Full Text] [Related]
4. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. Canuso CM; Ionescu DF; Li X; Qiu X; Lane R; Turkoz I; Nash AI; Lopena TJ; Fu DJ J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):516-524. PubMed ID: 34412104 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663 [TBL] [Abstract][Full Text] [Related]
7. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial. Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA. Chen X; Hou X; Bai D; Lane R; Zhang C; Canuso C; Wang G; Fu DJ Neuropsychiatr Dis Treat; 2023; 19():693-707. PubMed ID: 37025256 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study). Hong JP; Malek AZA; Li CT; Paik JW; Sulaiman AH; Madriaga G; Zhuo J; Siggins S; Fu DJ; Ju PC Asia Pac Psychiatry; 2023 Dec; 15(4):e12548. PubMed ID: 37771084 [TBL] [Abstract][Full Text] [Related]
11. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder". Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931 [TBL] [Abstract][Full Text] [Related]
14. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932 [TBL] [Abstract][Full Text] [Related]
15. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. Fu DJ; Zhang Q; Shi L; Borentain S; Guo S; Mathews M; Anjo J; Nash AI; O'Hara M; Canuso CM BMC Psychiatry; 2023 Aug; 23(1):587. PubMed ID: 37568081 [TBL] [Abstract][Full Text] [Related]
16. Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. Wang SM; Kim NY; Na HR; Lim HK; Woo YS; Pae CU; Bahk WM Clin Psychopharmacol Neurosci; 2021 May; 19(2):341-354. PubMed ID: 33888663 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742 [TBL] [Abstract][Full Text] [Related]
18. Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials. Borentain S; Williamson D; Turkoz I; Popova V; McCall WV; Mathews M; Wiegand F Neuropsychiatr Dis Treat; 2021; 17():3459-3470. PubMed ID: 34880615 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084 [TBL] [Abstract][Full Text] [Related]
20. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]